Philip McCullough
Psychiatry · Chicago, ILNPI 1396701371
Payments from drug & device makers
Across 186 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$927
- Lundbeck LLC$804
- Axsome Therapeutics, Inc.$340
- Otsuka America Pharmaceutical, Inc.$319
- Takeda Pharmaceuticals U.S.A., Inc.$310
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$304
- plus $662 from 10 others
What the payments were for
- Food & beverage$3,666100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $927 |
| Lundbeck LLC | 45 | $804 |
| Axsome Therapeutics, Inc. | 10 | $340 |
| Otsuka America Pharmaceutical, Inc. | 17 | $319 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $310 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $304 |
| Merck | 9 | $147 |
| Bausch Health US, LLC | 9 | $144 |
| Alfasigma USA, Inc. | 5 | $119 |
| Eisai Inc. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Johnson & Johnson | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Alkermes, Inc. | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$131
How this compares
$3,666 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 18 | $12,924 |
| BelsomraSuvorexant | 20 | $9,829 |
| DayvigoLemborexant | 20 | $6,727 |
| Phenelzine Sulfate | 15 | $2,348 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $1,954 |
| Duloxetine Hcl | 22 | $1,519 |
| Olanzapine | 13 | $1,361 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 52 | $920 |
| Bupropion Hcl SrBupropion Hcl | 75 | $856 |
| Alprazolam | 83 | $748 |
| Imipramine Hcl | 11 | $728 |
| Aripiprazole | 29 | $662 |
| Escitalopram Oxalate | 50 | $652 |
| Lamotrigine | 71 | $632 |
| Atomoxetine Hcl | 16 | $573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $310 | $12,92418 claims |
| MerckBelsomra | $147 | $9,82920 claims |
| Eisai Inc.Dayvigo | $67 | $6,72720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Chicago
- Yuhwen ChowChicago$8.5M
- Jon GrantChicago$1.4M
- Jeffrey RadoChicago$1.2M
- Mitchell GlaserChicago$1.1M
- Peter WeidenChicago$941K
- Brett PlylerChicago$293K
- Michelle DeesChicago$289K
- Jennifer SpragueChicago$288K
- K Ranga KrishnanChicago$92K
- Pawel DudekChicago$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.